The Technical Analyst
Acceleron Pharma Inc [XLRN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Acceleron Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $178.75
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-01-31 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 176.11 - 181.39 ( +/- 1.48%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-11-19 | Zakrzewski Joseph S | Sell | 34 499 | Common Stock |
| 2021-11-19 | Zakrzewski Joseph S | Sell | 10 000 | Option to Purchase Common Stock |
| 2021-11-19 | Zakrzewski Joseph S | Sell | 7 500 | Option to Purchase Common Stock |
| 2021-11-19 | Zakrzewski Joseph S | Sell | 7 500 | Option to Purchase Common Stock |
| 2021-11-19 | Zakrzewski Joseph S | Sell | 10 000 | Option to Purchase Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 100 transactions |
| Buy: 155 406 | Sell: 743 673 |
Forecast:
01:40 - $184.41
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $178.75 (0.00% ) |
| Volume | 7.88 mill |
| Avg. Vol. | 1.265 mill |
| % of Avg. Vol | 623.11 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XLRN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
XLRN
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2021-11-17 14:26:00 - Press Release
Avoro Capital Urges Acceleron Shareholders Not To Tender Into Merck's Inadequate Offer
New york--(business wire)--avoro capital advisors (“avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“avoro,” “we” or “us”) beneficially owns approximately 7% of acceleron pharma inc. (nasdaq: xlrn) (“acceleron,” “xlrn” or the “company”), making avoro one of the company's most significant shareholders. avoro today issued the following statement reiterating why it believes that shareholders sh
2021-11-09 17:31:00 - Press Release
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate Offer
New york--(business wire)--avoro capital advisors (“avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“avoro,” “we” or "us") beneficially owns approximately 7% of acceleron pharma inc. (nasdaq: xlrn) (“acceleron”, “xlrn” or the “company”), making avoro one of the company's most significant shareholders. avoro today released a detailed presentation outlining why shareholders should not tender t
2021-11-04 16:01:00 - Press Release
Acceleron Reports Third Quarter 2021 Financial Results
Cambridge, mass.--(business wire)--acceleron pharma inc. (nasdaq:xlrn), a biopharmaceutical company dedicated to the discovery, development, and commercialization of tgf-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the third quarter ended september 30, 2021. corporate highlights on september 30, merck (nyse: mrk), known as msd outside the united states and canada, and acceleron pharma inc. announced that the companies entered into a defi
2021-11-01 21:25:00 - Press Release
Shareholder Alert: Weisslaw Llp Reminds Dwsn, Pae, Xlrn, And Flxn Shareholders About Its Ongoing Investigations
New york, nov. 1, 2021 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq. weisslaw llp305 broadway, 7th floor new york, ny 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com dawson geophysical company (nasdaq: dwsn) weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of dawson geophysical company (nasdaq: dwsn) in connection with the proposed acquisition of dwsn by a subsidiary of wilks brothers, llc.
2021-10-28 08:00:00 - Press Release
Avoro Capital Issues Open Letter To Fellow Acceleron Pharma Shareholders
New york--(business wire)--avoro capital advisors (“avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of acceleron pharma inc. (nasdaq:xlrn) (“acceleron”, “xlrn” or the “company”) together with certain of its affiliates and managed funds (“avoro,” “we” or "us"), making it one of the company's most significant shareholders. avoro today issued an open letter to fellow acceleron shareholders further detailing why the pr
Latest News
2022-10-10 09:49:13 - Investors Business Daily
Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout
Merck stock jumped Monday after a drug its acquired for billions scored a "must-win" in patients with a rare blood pressure condition. The post Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout appeared first on Investor's Business Daily.
2021-11-12 07:31:00 - The Motley Fool
Is Merck's Planned Acquisition of Acceleron in Trouble?
2021-11-04 19:04:41 - Zacks Investment Research
Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates
Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-01 17:10:40 - Benzinga
Merck Pushes Acceleron Buyout By Refiling For Antitrust Review
Merck & Co Inc (NYSE: MRK) revealed that it had temporarily withdrawn its premerger notification and report form. The company said it plans to refile today.
2021-10-21 13:10:54 - Benzinga
Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg
Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed to buy the biotechnology company for $11.5 billion, Bloomberg reported citing people with knowledge of the matter. Bristol-Myers holds an 11.5% stake in Acceleron.
2021-10-13 17:56:00 - PRNewsWire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acceleron Pharma Inc. - XLRN
NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Acceleron Pharma Inc. ( XLRN ) relating to its proposed acquisition by Merck & Co., Inc. Under the terms of the agreement, XLRN shareholders are expected to receive $180.00 in cash per share they own. The investigation focuses on whether Acceleron Pharma Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
2021-10-13 16:09:00 - Reuters
Holocene Advisors says Merck's offer undervalues Acceleron
Investment management firm Holocene Advisors said it will not tender its shares in Acceleron Pharma Inc into Merck & Co's proposed $180 per share offer for the drugmaker, as it significantly undervalues the company.
2021-10-13 15:30:00 - Business Wire
Holocene Advisors Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company
NEW YORK--(BUSINESS WIRE)--Holocene Advisors, LP (“Holocene”), a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron” or the “Company”), today announced that it does not intend to tender its shares into Merck & Co.'s (NYSE: MRK) proposed $180 per share offer for the Company announced on September 30, 2021. Holocene stated the following: “As a large shareholder in Acceleron, we believe the Company's management team has done a
2021-10-08 06:05:00 - The Motley Fool
Is an Acquisition of Acceleron a Smart Move for Merck?
2021-10-04 10:30:17 - Forbes
With Acceleron Acquisition Merck Stock Is Likely To See A Multiple Revision
Merck yesterday announced that it will acquire Acceleron Pharma - a biopharmaceutical company focused on rare diseases - for $11.5 billion funded in cash and debt. Acceleron has multiple potentially blockbuster drugs in its pipeline.